Pharma Focus Asia

Gritstone Bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement

Wednesday, February 15, 2023

Gritstone announced that it has entered into a clinical trial agreement with the National Cancer Institute (NCI), to evaluate an autologous T cell therapy expressing a T cell receptor targeting mutated KRAS in combination with Gritstone’s KRAS-directed vaccine candidate, SLATE-KRAS, in a Phase 1 study.

NCI will lead the Phase 1 study using Gritstone’s proprietary “off the shelf” vaccine technology for mutant KRAS solid tumours.

Under the terms of the agreement, NCI will identify patients with metastatic cancer who are eligible for adoptive cell transfer based on the presence of a G12V or G12D KRAS mutation (KRASmut). Gritstone will provide the SLATE-KRAS vaccine as requested by NCI for the trial.

The use of neoantigen vaccines to enhance the potency of neoantigen-directed T cell therapy is an attractive concept with supportive pre-clinical data. The KRAS-directed vaccine has demonstrated the ability to induce and expand KRASmut-specific T cells and drive into solid tumours in multiple clinical studies. This approach to potentially deepening and extending the therapeutic effect of TCR-T will provide improved outcomes to solid tumour patients.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024